11/20
03:11 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/15
02:08 pm
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target lowered by analysts at TD Cowen from $160.00 to $153.00. They now have a "buy" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target lowered by analysts at TD Cowen from $160.00 to $153.00. They now have a "buy" rating on the stock.
11/15
11:13 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $190.00 to $180.00. They now have an "outperform" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $190.00 to $180.00. They now have an "outperform" rating on the stock.
11/15
10:27 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.
11/15
09:11 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Stifel Nicolaus from $200.00 to $207.00. They now have a "buy" rating on the stock.
Medium
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Stifel Nicolaus from $200.00 to $207.00. They now have a "buy" rating on the stock.
11/15
08:17 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $181.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $181.00 price target on the stock.
11/14
04:01 pm
asnd
Ascendis Pharma Reports Third Quarter 2024 Financial Results
Low
Report
Ascendis Pharma Reports Third Quarter 2024 Financial Results
11/13
12:08 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/7
04:18 pm
asnd
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 [Yahoo! Finance]
Low
Report
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 [Yahoo! Finance]
11/7
04:01 pm
asnd
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
Low
Report
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
11/6
06:32 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at Wedbush to a "strong-buy" rating.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at Wedbush to a "strong-buy" rating.
11/4
01:33 pm
asnd
Hypoparathyroidism Market to Grow by USD 474.9 Million from 2024-2028, Driven by Thyroid Treatment Awareness Programs and AI-Powered Market Insights - Technavio
Low
Report
Hypoparathyroidism Market to Grow by USD 474.9 Million from 2024-2028, Driven by Thyroid Treatment Awareness Programs and AI-Powered Market Insights - Technavio
11/4
09:31 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.
11/4
07:00 am
asnd
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
Low
Report
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
10/23
08:18 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target lowered by analysts at JPMorgan Chase & Co. from $180.00 to $174.00. They now have an "overweight" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target lowered by analysts at JPMorgan Chase & Co. from $180.00 to $174.00. They now have an "overweight" rating on the stock.
10/21
02:22 pm
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at TD Cowen from $157.00 to $160.00. They now have a "buy" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at TD Cowen from $157.00 to $160.00. They now have a "buy" rating on the stock.
10/8
03:19 pm
asnd
MBX Bio drops despite bullish views on Street Oct. 08, 2024 3:15 PM ET By: Dulan Lokuwithana , SA News Editor [Seeking Alpha]
Low
Report
MBX Bio drops despite bullish views on Street Oct. 08, 2024 3:15 PM ET By: Dulan Lokuwithana , SA News Editor [Seeking Alpha]
10/1
11:13 am
asnd
Ascendis Pharma submits sBLA for growth hormone deficiency therapy [Yahoo! Finance]
Low
Report
Ascendis Pharma submits sBLA for growth hormone deficiency therapy [Yahoo! Finance]
9/30
08:30 am
asnd
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
Medium
Report
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
9/30
08:30 am
asnd
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
Medium
Report
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
9/30
07:00 am
asnd
GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer
Medium
Report
GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer
9/26
05:31 pm
asnd
Global Hormone Replacement Therapy Market to Grow Substantially at a CAGR of ~6% by 2030 | DelveInsight
Low
Report
Global Hormone Replacement Therapy Market to Grow Substantially at a CAGR of ~6% by 2030 | DelveInsight
9/26
05:31 pm
asnd
Global Hormone Replacement Therapy Market to Grow Substantially at a CAGR of ~6% by 2030 | DelveInsight
Low
Report
Global Hormone Replacement Therapy Market to Grow Substantially at a CAGR of ~6% by 2030 | DelveInsight
9/24
11:19 am
asnd
Citi's ‘Catalyst Watch' list of U.S. stocks for crowding analysis [Seeking Alpha]
Low
Report
Citi's ‘Catalyst Watch' list of U.S. stocks for crowding analysis [Seeking Alpha]
9/23
12:15 pm
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Bank of America Co. from $175.00 to $191.00. They now have a "buy" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Bank of America Co. from $175.00 to $191.00. They now have a "buy" rating on the stock.